Chattem R&D
This article was originally published in The Rose Sheet
Executive Summary
Health and beauty aids manufacturer will break ground for $2 mil., 10,000 sq.-ft. research and development facility in Chattanooga, Tenn. in February, company announces. Research facility, which is slated for completion by end of calendar year, will be dedicated to creating line extensions for existing products, according to President, Chief Operating Officer Alec Taylor. Gold Bond sales are expected to be $40 mil.- $42 mil. in 2002, and pHisoderm annual sales are expected to be in $15 mil.-$17 mil. range, Taylor reports during 1presentation at Banc of America Securities Equity and High Yield Research Household Products Conference Jan. 10...
You may also be interested in...
Chattem Gold Bond, pHisoderm Extensions To Launch In Coming Months
Chattem is gearing up to launch a slew of new product line extensions within the next few months as its decision to increase its investment in R&D over the past two years begins to pay dividends
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.